John Hood, CEO, Endeavor BioMedicines discusses the key differences between ENV-101 and currently approved IPF treatments. PE: How does the initiation of the WHISTLE-PF trial fit into Endeavor ...

How improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes Challenges healthcare marketers face in ...

Harpreet Gill, vice president of real-world solutions - project management at ICON, discussesthe progress and challenges in advancing data-driven tools and approaches in decentralized clinical trials, ...

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses regulatory challenges and opportunities that telehealth companies face in 2025. In this ...

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, explores the key factors driving the increasing number of partnerships between telehealth and ...

In the third part of this roundtable discussion, experts discuss the issues with data that AI must overcome. Pharmaceutical Executive recently brought together a group of experts to discuss the ...

Accelerated approval was based on promising results from the ongoing Phase III BREAKWATER trial. The FDA has granted accelerated approval to Pfizer’s Braftovi (encorafenib) in combination with ...

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, shares some specific examples of how AI is being used to personalize treatment plans, monitor patient ...

John Aiken, Senor Director, Training & Talent Development, Veloxis Pharmaceuticals;Jennifer Troiano, Territory Manager, Sandoz Pharmaceuticals;Kumar Erramilli, Chief ...

Approval marks the first generic version of liraglutide injection, referencing Victoza, for improving glycemic control in adults and children aged 10 years and older with type 2 diabetes, alongside ...

New technology is making it easier for more companies to embrace telehealth, which in turn is providing more opportunities for pharma companies to interact with HCPs and patients. Peter Ax, founder ...

GLP-1s are the most discussed drug of 2024. While they were initially developed to treat diabetes, the drug’s ability to help with weight loss has made them extremely popular. So much so that in 2023, ...